Cybin Valuation
Is R7E undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of R7E when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: R7E (€9.45) is trading below our estimate of fair value (€1031.44)
Significantly Below Fair Value: R7E is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for R7E?
Key metric: As R7E is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is R7E's PB Ratio? | |
|---|---|
| PB Ratio | 1.1x |
| Book | CA$255.02m |
| Market Cap | CA$289.03m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does R7E's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.8x | ||
PSG PharmaSGP Holding | 8.6x | 13.9% | €280.6m |
93M1 MPH Health Care | 0.3x | -65.7% | €105.3m |
2FJ0 Pierrel | 3.6x | n/a | €92.8m |
APPH Apontis Pharma | 2.6x | 78.1% | €80.3m |
R7E Cybin | 1.1x | 48.8% | €206.8m |
Price-To-Book vs Peers: R7E is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (3.8x).
Price to Book Ratio vs Industry
How does R7E's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 11 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: R7E is good value based on its Price-To-Book Ratio (1.1x) compared to the European Pharmaceuticals industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is R7E's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate R7E's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €9.45 | €98.55 +942.8% | 57.1% | €180.39 | €23.74 | n/a | 4 |
| Nov ’25 | €8.85 | €141.83 +1,502.6% | 34.4% | €207.01 | €85.65 | n/a | 4 |
| Oct ’25 | €7.59 | €142.55 +1,778.1% | 34.7% | €208.59 | €86.30 | n/a | 4 |
| Sep ’25 | €7.95 | €145.91 +1,734.6% | 30.5% | €207.04 | €103.36 | n/a | 4 |
| Aug ’25 | €9.25 | €149.49 +1,516.9% | 27.2% | €208.86 | €104.43 | n/a | 5 |
| Jul ’25 | €8.82 | €151.99 +1,624.1% | 27.1% | €213.08 | €106.54 | n/a | 5 |
| Jun ’25 | €11.89 | €156.36 +1,214.6% | 21.9% | €207.55 | €105.40 | n/a | 5 |
| May ’25 | €12.16 | €169.56 +1,294.4% | 15.2% | €208.51 | €139.02 | n/a | 4 |
| Apr ’25 | €14.29 | €169.56 +1,086.7% | 15.2% | €208.51 | €139.02 | n/a | 4 |
| Mar ’25 | €11.40 | €171.49 +1,404.3% | 15.2% | €211.07 | €140.63 | n/a | 4 |
| Feb ’25 | €12.16 | €179.72 +1,377.9% | 10.8% | €210.22 | €156.39 | n/a | 4 |
| Jan ’25 | €13.22 | €180.07 +1,261.7% | 10.5% | €209.70 | €157.28 | n/a | 4 |
| Dec ’24 | €15.05 | €180.07 +1,096.6% | 10.5% | €209.70 | €157.28 | n/a | 4 |
| Nov ’24 | €20.71 | €200.78 +869.5% | 47.5% | €359.62 | €105.80 | €8.85 | 4 |
| Oct ’24 | €16.80 | €197.26 +1,074.4% | 49.0% | €358.96 | €107.98 | €7.59 | 4 |
| Sep ’24 | €10.41 | €193.40 +1,757.4% | 49.2% | €352.25 | €104.85 | €7.95 | 4 |
| Aug ’24 | €10.64 | €182.82 +1,618.3% | 49.2% | €345.40 | €103.14 | €9.25 | 5 |
| Jul ’24 | €13.15 | €192.53 +1,364.3% | 46.5% | €348.09 | €104.44 | €8.82 | 5 |
| Jun ’24 | €9.42 | €203.16 +2,055.8% | 46.8% | €358.06 | €105.99 | €11.89 | 5 |
| May ’24 | €11.32 | €204.14 +1,702.7% | 46.8% | €359.72 | €106.58 | €12.16 | 5 |
| Apr ’24 | €12.47 | €204.14 +1,537.4% | 46.8% | €359.72 | €106.58 | €14.29 | 5 |
| Mar ’24 | €17.07 | €208.30 +1,120.0% | 41.3% | €351.50 | €107.00 | €11.40 | 5 |
| Feb ’24 | €13.55 | €205.76 +1,418.0% | 39.0% | €356.45 | €106.52 | €12.16 | 6 |
| Jan ’24 | €11.09 | €206.83 +1,764.7% | 39.0% | €358.47 | €107.13 | €13.22 | 6 |
| Dec ’23 | €13.04 | €256.11 +1,864.4% | 31.5% | €367.38 | €146.94 | €15.05 | 6 |
| Nov ’23 | €17.30 | €289.65 +1,574.5% | 29.7% | €371.12 | €150.65 | €20.71 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$16.25
7D
2.5%
1Y
89.8%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%